Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
一项针对B细胞恶性肿瘤的选择性、非共价、可逆性布鲁顿酪氨酸激酶抑制剂vecabrutinib的Ib期剂量递增研究
期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2021.280061
Allan, John N; Pinilla-Ibarz, Javier; Gladstone, Douglas E; Patel, Krish; Sharman, Jeff P; Wierda, William G; Choi, Michael Y; O'Brien, Susan M; Shadman, Mazyar; Davids, Matthew S; Pagel, John M; Yimer, Habte A; Ward, Renee; Acton, Gary; Taverna, Pietro; Combs, Daniel L; Fox, Judith A; Furman, Richard R; Brown, Jennifer R